Limes Schlosskliniken AG (LIK) AI Stock Analysis

• Market Cap: €126.60M
• Dividend Yield: N/A
• Average Volume (3M): 37.00
• Price to Earnings (P/E): 26.9
• Beta (1Y): -0.24
• Revenue Growth: 0.21%
• EPS Growth: 7.53%
• Country: DE
• Employees: 210
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 11.30
• Shares Outstanding: 300,000
• 10 Day Avg. Volume: 27
• 30 Day Avg. Volume: 37
• PEG Ratio: -3.73
• Price to Book (P/B): 5.31
• Price to Sales (P/S): 2.60
• P/FCF Ratio: 39.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: €471.00 ▲(30.83% Upside)

Limes Schlosskliniken AG's overall stock score reflects strong financial performance and stable valuation, balanced by mixed technical indicators. The company's robust revenue and profit growth, along with effective cash flow management, are significant strengths. However, technical analysis suggests potential caution due to bearish momentum indicators, and the valuation indicates moderate pricing relative to peers.

Positive Factors

Sustained revenue growth

Consistent annual revenue expansion from 2019–2024 and a 20.7% reported revenue growth rate indicate durable demand for the company's care services. This trend supports reinvestment, scale advantages in operations, and a stable revenue base for multi-year planning and margin improvement.

High and improving margins

Sustained high gross margins plus improving net profit margins and robust EBIT/EBITDA margins point to structural cost control and service mix advantages. These margins create long-term operating leverage, enabling the company to absorb reimbursement or wage pressures while funding growth.

Strong balance sheet and equity growth

An increasing equity base and a manageable debt-to-equity ratio provide financial resilience and optionality. This durable capital structure supports capital expenditures, targeted acquisitions, and working capital needs without unduly raising solvency risk or constraining strategic investment over the medium term.

Negative Factors

Significant capital expenditure needs

Although free cash flow recovered, persistent and sizable capex reduces free cash flow cushion and limits flexibility for acquisitions, dividend initiation, or debt reduction. Ongoing high investment needs can strain liquidity during slower revenue periods or if operating cash generation weakens.

Earnings pressure (EBIT dip)

A year-over-year dip in EBIT signals emerging margin pressure that could reflect rising labor, input, or reimbursement costs. If structural, this trend may compress operating leverage and force efficiency or pricing actions to sustain profitability over the next several quarters.

Limited scale and public liquidity

A relatively small workforce and very low average trading volume indicate limited operational scale and public-market liquidity. This constrains geographic or service expansion, makes financing or large share transactions harder, and raises vulnerability to localized demand shocks over time.

Limes Schlosskliniken AG Business Overview & Revenue Model

Company Description

LIMES Schlosskliniken AG operates private hospitals for psychiatry, psychotherapy, and psychosomatics services. It focuses on the treatment of stress-related illnesses, as well as mental and emotional disorders, such as depression, acute burnout, affective disorders, and trauma. The company is headquartered in Cologne, Germany. LIMES Schlosskliniken AG is a subsidiary of GMF Capital Gmbh.

How the Company Makes Money

Limes Schlosskliniken AG generates revenue primarily through its healthcare services, including inpatient and outpatient rehabilitation programs, which are often covered by health insurance. The company receives payments from statutory and private health insurers for the medical services provided to patients. Additional revenue streams come from partnerships with healthcare providers and referral networks, enabling LIK to attract a steady flow of patients. Moreover, the company may also benefit from ancillary services such as wellness offerings and preventive health programs, contributing further to its earnings. The successful implementation of modern treatment methodologies and a focus on high-quality patient care play a significant role in maintaining and growing its revenue base.

Limes Schlosskliniken AG Financial Statement Overview

Summary

Limes Schlosskliniken AG exhibits strong financial health with robust revenue and profit growth, efficient operations, and a stable balance sheet. The company demonstrates effective cash flow management, enhancing liquidity. While the debt level is manageable, continued focus on maintaining operational efficiency and prudent capital investment will be essential to sustain growth and mitigate risks.

Income Statement

Limes Schlosskliniken AG has demonstrated a strong revenue growth trajectory, increasing its total revenue annually from 2019 to 2024. The gross profit margin has been consistently high, indicating efficient cost management. The net profit margin has improved significantly, reflecting enhanced profitability. EBIT and EBITDA margins are robust, showcasing operational efficiency. However, a slight dip in EBIT in 2024 suggests some pressure on earnings.

Balance Sheet

The balance sheet reveals a solid equity position with an increasing stockholders' equity from 2019 to 2024. The company maintains a manageable debt-to-equity ratio, indicating prudent leverage levels. The equity ratio signifies a strong financial base with a significant portion of assets funded by equity. Despite a slight increase in total debt, the company's equity growth offsets potential risks, sustaining a stable financial structure.

Cash Flow

Cash flow analysis shows a positive trend in operating cash flow, suggesting healthy cash generation from core operations. The free cash flow has recovered from negative values in earlier years to positive in recent periods, reflecting improved cash management. The operating cash flow to net income ratio supports stability, although capital expenditures remain significant, potentially impacting future liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	41.87M	37.45M	37.17M	28.81M	23.43M	11.02M
Gross Profit	19.04M	34.50M	16.23M	10.82M	8.37M	2.80M
EBITDA	9.73M	7.05M	7.67M	8.65M	6.02M	837.74K
Net Income	4.60M	3.11M	3.40M	4.20M	3.94M	-694.42K
Balance Sheet
Total Assets	43.72M	38.56M	33.25M	26.65M	18.44M	11.79M
Cash, Cash Equivalents and Short-Term Investments	11.10M	10.88M	8.52M	10.93M	2.48M	2.68M
Total Debt	12.29M	10.48M	10.09M	9.04M	4.33M	3.85M
Total Liabilities	20.16M	18.72M	16.61M	15.45M	12.13M	9.11M
Stockholders Equity	22.05M	18.33M	15.13M	11.10M	6.31M	2.68M
Cash Flow
Free Cash Flow	627.04K	2.48M	-3.51M	6.35M	-1.83M	-1.00M
Operating Cash Flow	8.49M	7.46M	6.29M	7.70M	4.55M	759.00K
Investing Cash Flow	-7.71M	-4.96M	-9.79M	-1.31M	-6.38M	-1.83M
Financing Cash Flow	2.65M	-159.15K	1.09M	2.04M	1.40M	2.53M

Limes Schlosskliniken AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 360.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:LIK, the sentiment is Positive. The current price of 360 is below the 20-day moving average (MA) of 392.60, below the 50-day MA of 362.24, and above the 200-day MA of 354.52, indicating a bullish trend. The MACD of 16.92 indicates Negative momentum. The RSI at 63.12 is Neutral, neither overbought nor oversold. The STOCH value of 76.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:LIK.

Limes Schlosskliniken AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MED	77 Outperform	€184.30M	5.26	15.25%	1.12%	4.90%	―
M12	74 Outperform	€342.93M	19.20	15.61%	2.80%	6.52%	7.17%
LIK	73 Outperform	€126.60M	26.92	23.66%	―	0.21%	7.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MAK	41 Neutral	€21.18M	-1.58	―	―	6.87%	-94.85%